Early detection rate changes from a brain-responsive neurostimulation system predict efficacy of newly added antiseizure drugs.

In RNS System patients with stable detection settings, when new ASDs are started, detection rates within the first 1-2 weeks may provide an early, objective indication of efficacy. These data could be used to identify responses to medication trials early to allow more rapid medication adjustments than conventionally possible.